The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Asasantin Retard 200mg/25mg Modified Release Hard Capsules

200/25 milligram(s) Capsules Modified Release

Imbat LimitedPPA1151/128/001

Main Information

Trade NameAsasantin Retard 200mg/25mg Modified Release Hard Capsules
Active SubstancesAspirin
Strength200/25 milligram(s)
Dosage FormCapsules Modified Release
Licence HolderImbat Limited
Licence NumberPPA1151/128/001

Group Information

ATC CodeB01AC Platelet aggregation inhibitors excl. heparin
B01AC30 combinations


Licence Issued27/11/2009
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown


Summary of Product CharacteristicsPDF Version
Package LeafletNo document available
Public Assessment ReportNo document available
« Back